Idenix Pharmaceuticals (IDIX)

[keitern]

Market cap almost exactly equal to cash again. Tyzeka, HCV, HIV programs worth nothing. The last Q's 25M cash expended from the treasury has been given no value. I must say, all the money NVS has spent on the IDIX development team has been and continues to be extraordinary.
The analysts genuinely seem to like JP. I myself, this listen, do like the man more. I hope all this valuation nonsense straightens itself out. If not, it sure won't be the only bio tech hole that money has been chased down.

It seems like the story here is 100X potency => once daily dose with wiggle room to fine tune safety on the HBV. But the HBV trials are going to consume more time and money. Will and/or to what extent will NVS carry the financing of the HBV trials. With the 1st gen NVS was paying for the trials 100% at the end, right? Will the same model hold?